IPCALAB · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 47/100 — Quality 65 · Valuation 25 · Growth 24 · Momentum 78
| Share price | ₹1,950.30 |
| Market cap | ₹38,930 Cr |
| P/E ratio | 42.6 |
| P/B ratio | 4.7 |
| ROE | 17.1% |
| ROCE | 16.4% |
| Dividend yield | 0.26% |
| Book value | ₹324.60 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹9,599 Cr | ₹1,184 Cr | 21.0% |
| 2025 | ₹8,897 Cr | ₹785 Cr | 19.0% |
| 2024 | ₹7,662 Cr | ₹523 Cr | 17.0% |
| 2023 | ₹6,204 Cr | ₹479 Cr | 15.0% |
| 2022 | ₹5,797 Cr | ₹890 Cr | 23.0% |
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive,